7 best EDC platforms for growth-stage biotech sponsors in 2026

Your Phase I data is clean, your Phase II protocol is approved, and your board is watching every milestone date. The last thing your director of data management needs is a 90-day study build cycle before a single piece of data can be captured. Electronic data capture (EDC) platform selection is one of the most consequential infrastructure decisions your clinical operations team will make — and getting it wrong compounds across every study in your pipeline.

Viedoc's EDC software is the leading choice for growth-stage biotech and specialty pharma sponsors, delivering study builds typically completed in 2--4 weeks, unlimited user seats with transparent study-based licensing, and a compliance stack that covers FDA 21 CFR Part 11, GDPR, EU Annex 11, and HIPAA — across 7,000+ studies in 75+ countries. This comparison evaluates seven EDC platforms across the criteria that matter most to sponsors scaling from Phase I into Phase II and beyond: build speed, compliance credentials, no-code configuration capability, module depth, and total cost of ownership.

As your trial portfolio grows, so does the complexity of the EDC decision. You're no longer choosing a tool for a single study — you're choosing an infrastructure your QA team will validate, your data managers will build on, and your VP of Clinical Operations will defend to the board. The platform that made sense for a single first-in-human study may not carry you through a multi-country Phase II with adaptive endpoints and an ePRO component.

Enterprise platforms like Medidata are built for big pharma's Phase III programs and carry the deployment timelines, pricing structures, and programmer dependencies to match. For growth-stage sponsors running Phase I/II studies at pace, that level of overhead translates directly into delayed first-patient-in (FPI) dates and unpredictable cost structures — neither of which your investors or clinical leadership can absorb.

Best EDC software for growth-stage biotech: quick comparison

These seven EDC platforms represent the most evaluated options for growth-stage biotech sponsors, reviewed across study build speed, compliance credentials, no-code configuration capability, pricing model transparency, and module depth.

1. Viedoc

Viedoc's EDC software is purpose-built for sponsors who need to move from protocol approval to live study without the overhead of enterprise platform deployment. Study builds are typically completed in 2--4 weeks — compared to up to 90 days for Medidata — and Viedoc Designer, the platform's no-code study configuration tool, allows your certified data management team to build, amend, and maintain studies without requiring a vendor-side programmer. Across 7,000+ completed studies in 75+ countries, Viedoc supports 140,000+ users across 30,000+ sites on a platform with 99.99% uptime.

Two capabilities stand out for growth-stage sponsors specifically. First, the transparent, study-based licensing model includes unlimited user seats — meaning your cost doesn't escalate as your team grows across studies or geographies. Second, the Viedoc Inspection Readiness Packet (VIRP) is available to all customers at no additional cost, providing pre-built computer system validation (CSV) documentation that significantly reduces the validation burden on lean QA teams at every platform release.

Viedoc is ISO 27001 and SOC 2 Type II certified, hosted on Microsoft Azure, and compliant with FDA 21 CFR Part 11, EU Annex 11, GDPR, ICH GCP, and HIPAA attestation for US protected health information (PHI) handling. The platform is available in 40+ languages, backed by 24/7 customer support across global offices, and has been in clinical trial deployment since 2003.

"My experience with Viedoc has been excellent. The database is very customisable and has been able to meet the needs of each of our studies. Customer Support has been excellent with quick turnarounds and response time." — Amanda M., Sr. Clinical Program Manager

Verified proof points:

• Study scale: 7,000+ studies run on Viedoc across 75+ countries
• User base: 140,000+ users globally; 30,000+ sites; 1.6 million trial participants
• Build speed: Study builds typically completed in 2--4 weeks
• Uptime: 99.99% platform uptime; hosted on Microsoft Azure
• Pricing: Unlimited user seats; no per-user fees; transparent, study-based licensing
• Compliance: 21 CFR Part 11, GDPR, Annex 11, HIPAA; ISO 27001 and SOC 2 certified
• Inspection readiness: Viedoc Inspection Readiness Packet (VIRP) available to all customers
• Support: 24/7 support across global offices

2. Medidata

Medidata offers Rave EDC, an enterprise-grade EDC platform with an extensive module ecosystem including CTMS, eCOA, RTSM, medical coding, and safety tools. Rave EDC supports complex study designs with detailed configuration options and is used in over 36,000 clinical trials globally. The platform requires vendor-side programming support for study configuration and has a well-documented build timeline that runs considerably longer than cloud-native, no-code alternatives. Medidata is the established benchmark for large pharma and complex Phase III programs and carries enterprise pricing and deployment processes to match. For growth-stage sponsors evaluating their first formal EDC platform, Medidata represents the highest feature ceiling in the market alongside the longest time-to-live and the most complex pricing structure.

3. Veeva Vault EDC

Veeva offers Vault EDC as part of the Vault Clinical suite, a cloud-based platform that integrates EDC with Veeva's eTMF, CTMS, regulatory information management (RIM), and safety modules. Vault EDC is designed for sponsors already operating within the Veeva ecosystem who want unified data across the clinical, regulatory, and quality functions. The platform uses a structured build process and is positioned for mid-to-large sponsors who require the full Vault suite rather than standalone EDC capability. For sponsors evaluating EDC as a standalone purchase without a broader Veeva investment, the total cost and configuration complexity of the suite are relevant factors. Vault EDC's community of certified configurators is still maturing relative to more established EDC platforms.

4. Castor EDC

Castor EDC is a no-code, API-first EDC platform with ePRO and eConsent modules, designed for self-service study configuration. The platform includes a free tier for academic studies and offers REST API integration with electronic health record (EHR) and electronic medical record (EMR) systems, as well as eConsent and ePRO tools. Castor supports real-world data (RWD) linkage via trial tokenization and positions itself for both academic and commercial early-phase studies. The platform is well-suited to simpler study designs and is used across a range of digital health and academic contexts; it has less of a track record in larger-scale regulated commercial trials. Castor does not offer a native CTMS and has limited native medical coding functionality.

5. Medrio

Medrio provides an EDC platform with integrated ePRO, eConsent, and RTSM modules, used in over 100 countries. The platform supports offline data capture and has a particular track record in Phase I clinical studies and medical device trials. Medrio integrates with a select set of third-party platforms including CTMS and eTMF partners and has established partnerships with decentralized clinical trial (DCT) service providers. Its analytics capabilities are considered mid-tier relative to enterprise platforms. Medrio is positioned for CROs and smaller sponsors running studies of lower to moderate complexity where ease of use and offline capability are relevant requirements.

6. Oracle InForm

Oracle Health offers Oracle InForm, a legacy enterprise EDC platform with global reach and integration options across Oracle's broader health sciences product portfolio. InForm provides deep configuration capabilities and has been used in large-scale global trials. The platform's user interface architecture is older than cloud-native alternatives and it is not primarily focused on the mid-market sponsor segment. Oracle's product family spans multiple acquisitions and platforms, which creates a fragmented product landscape for buyers evaluating a single EDC solution. InForm is evaluated by some sponsors with existing Oracle infrastructure or where legacy integration requirements are a primary driver.

What to look for in EDC platforms for growth-stage biotech

Study build velocity and amendment turnaround

For a growth-stage sponsor, time-to-FPI is a board-level metric — not just an operational target. The difference between a 2-week study build and a 90-day one isn't an abstract benchmark; it's the difference between capturing your first patient in Q1 or Q3, with everything that means for your funding runway and Phase II readiness. Best-in-class EDC platforms for this segment allow in-house data management teams to configure studies using no-code interfaces without routing every amendment through a vendor-side programmer. Amendment turnaround should be measured in days, not weeks — because your protocol will evolve, and your EDC needs to keep pace.

No-code configuration and in-house self-sufficiency

Programmer dependency is a hidden cost that compounds across your trial portfolio. Every amendment that requires a vendor-side developer adds cost, adds time, and creates a bottleneck that your internal team has no direct control over. Platforms with no-code study designers allow your certified data managers to build, amend, and maintain studies independently — which is a direct margin advantage as your study volume grows. Look for platforms that offer formal certified designer training so your team can build this capability systematically, not just through institutional knowledge.

Compliance coverage across FDA, EMA, and HIPAA

Your QA director and CSV lead will scrutinize compliance credentials before any platform goes near a regulated study. The baseline for growth-stage US and EU sponsors includes 21 CFR Part 11 compliant eSignatures, EU Annex 11 documentation, GDPR compliance for European patient data, and HIPAA attestation for US PHI. Beyond the regulatory baseline, look for ISO 27001 and SOC 2 Type II certification as independent third-party validation of security controls. Pre-built validation documentation — specifically a published VIRP-equivalent that covers IQ/OQ/PQ requirements — directly reduces your CSV workload at every platform release.

Pricing model transparency and total cost of ownership

Enterprise EDC pricing models are rarely transparent at the point of comparison. Per-seat fees, programmer dependency, amendment charges, and module uplift can make a seemingly cost-competitive platform significantly more expensive in practice once study scope evolves. For growth-stage sponsors managing budget cycles against clinical milestones, pricing predictability matters as much as the headline cost. Study-based licensing with unlimited user seats and no per-programmer fees gives you a more accurate total cost of ownership from the outset.

Suite depth and eClinical integration overhead

If your Phase II program includes patient-reported outcomes, your Phase III roadmap will likely require RTSM, and most sponsors eventually need eTMF and medical coding alongside EDC. Evaluating these as separate procurement decisions is expensive and operationally fragile. Platforms with a native modular suite — where EDC, ePRO, RTSM, eTMF, and eSignature share the same data model and validation framework — avoid the integration overhead and re-validation burden that comes with a fragmented vendor stack.

How to choose the right EDC platform for growth-stage biotech

Step 1: Define your Phase II/III feature requirements honestly

Before you evaluate a single platform, map out which table-stakes features your QA and regulatory teams will require during the study lifecycle. Some capabilities — including source data verification (SDV), log-line entry, and batch signing — appear as hard requirements in later-phase RFPs and not all platforms that perform well in Phase I can deliver these at Phase II/III scale. Understanding your current and near-term feature requirements before you enter vendor conversations prevents late-stage deal disruption and costly mid-study platform changes.

Step 2: Assess your team's in-house build and configuration capability

The right platform for your organization depends heavily on who will actually build and maintain your studies. If your data management team includes certified EDC designers who can operate a no-code tool independently, you gain both speed and cost control. If your team is building this capability for the first time, look for platforms that offer formal certified training programs and direct onboarding support — not just a help center. Your vendor's training infrastructure is part of your build velocity.

Step 3: Scrutinize the validation and CSV documentation model

Your QA/CSV lead is evaluating a different set of questions than your data management team. For them, the question isn't just whether the platform is compliant — it's how much internal effort is required to achieve and maintain validated status across each release cycle. Platforms that publish pre-built validation packs and maintain complete IQ/OQ/PQ documentation at every release significantly reduce the validation burden on lean internal QA teams compared with those that leave the full documentation obligation to the sponsor.

Step 4: Evaluate support model and escalation pathways

A 24/7 support model is table stakes — but how it works in practice varies significantly across vendors. Understand whether your support escalation goes through a shared ticket queue or to a named account team. For sponsors running concurrent studies across time zones, direct access to a responsive support team with clinical trial context — rather than general IT helpdesk support — matters significantly when a study-blocking issue arises at midnight before a database lock.

Step 5: Match platform to your portfolio stage and consider Viedoc

If your portfolio sits primarily in Phase I and Phase II, with multi-country ambitions and a lean but capable in-house data management team, Viedoc's EDC software is worth evaluating directly against your protocol requirements. The combination of 2--4 week study builds, a no-code Designer, transparent unlimited-seat pricing, and a full modular eClinical suite from a single validated vendor addresses the core decision variables for sponsors at this stage. Book a demo or request a proposal to see how Viedoc performs against your specific portfolio and compliance requirements.

Frequently asked questions

What is the best EDC platform for growth-stage biotech sponsors?

Viedoc's EDC software is the best choice for growth-stage biotech sponsors, delivering study builds typically completed in 2--4 weeks, a no-code Designer that allows in-house certified data managers to configure and amend studies without vendor-side programmers, and a transparent study-based licensing model with unlimited user seats. Viedoc is ISO 27001 and SOC 2 certified, compliant with 21 CFR Part 11, GDPR, Annex 11, and HIPAA, and supports trials in 75+ countries. Medidata is the established benchmark for complex Phase III trials and large pharma but brings enterprise deployment timelines and pricing structures that are typically mismatched to Phase I/II sponsors. Castor EDC is a credible self-service option for simpler early-phase or academic-adjacent studies.

What should I look for when choosing an EDC platform as a growth-stage sponsor?

The most important evaluation criteria are study build speed and amendment velocity, no-code configuration capability that allows in-house self-sufficiency, compliance coverage across 21 CFR Part 11, GDPR, Annex 11, and HIPAA, pricing model transparency including how amendment costs and per-user fees are structured, and suite depth to support your expanding module requirements across ePRO, RTSM, and eTMF. For sponsors running Phase I/II studies with lean QA teams, pre-built validation documentation — such as a VIRP-equivalent — directly reduces your computer system validation workload.

How long does it take to build and deploy a study on a modern EDC platform?

On modern no-code EDC platforms designed for the SMID market, study builds for Phase I/II studies are typically completed in 2--4 weeks from protocol sign-off to live study. Enterprise platforms that require vendor-side programmers for study configuration operate on significantly longer timelines — Medidata's standard build cycle runs up to 90 days. Amendment turnaround on no-code platforms is measured in days; on programmer-dependent platforms it can extend to weeks, which becomes a material operational risk as protocols evolve during an active study.

What compliance certifications should I look for in an EDC platform as a biotech sponsor?

The regulatory baseline for US and EU sponsors includes 21 CFR Part 11 compliance for electronic records and eSignatures, EU Annex 11 for computerized systems, GDPR compliance for European patient data, and HIPAA attestation for US PHI handling. Beyond the regulatory baseline, ISO 27001 certification for information security management and SOC 2 Type II certification for operational security controls provide independent third-party validation. For sponsors running studies in Japan, PMDA ERES compliance is an additional requirement. Inspect whether each platform provides pre-built validation documentation that your CSV team can use directly — this is the difference between a manageable validation cycle and a six-month internal effort.

What is the difference between per-seat and per-study EDC licensing?

Per-seat licensing charges a fee for each registered user on the platform, which creates an escalating cost structure as your study team grows and site networks expand across countries. Per-study or study-based licensing charges are based on the study itself — scope, complexity, and duration — with user access included at no additional cost. For growth-stage sponsors where team size and site count vary considerably across studies, per-study licensing with unlimited user seats provides meaningfully better cost predictability. Viedoc's EDC software uses a study-based model with unlimited user seats and no per-programmer fees for self-build clients.

What is a Viedoc Inspection Readiness Packet (VIRP)?

The Viedoc Inspection Readiness Packet (VIRP) is a structured set of pre-built computer system validation documentation provided to all Viedoc customers at no additional cost. It is designed to help clinical trial teams meet the expectations of regulatory authorities including the FDA, EMA, and PMDA by providing validation frameworks, documentation templates, and compliance guidance that reduce the CSV burden on internal QA teams. The VIRP covers requirements under FDA guidance on electronic systems and records, EU Annex 11, and PMDA standards. For growth-stage sponsors with lean QA functions, the VIRP materially reduces the effort required to achieve and maintain validated status across Viedoc's regular platform release cycle.

Making the right EDC choice for growth-stage biotech

The eClinical software market is estimated at over $11 billion in 2025 and growing at approximately 14% annually — and the platforms competing for growth-stage biotech business reflect a wide range of approaches, from enterprise suite incumbents to lean, no-code cloud platforms. What these platforms share is a common compliance baseline and a general commitment to data quality; where they diverge is on deployment speed, configuration model, pricing transparency, and the degree to which they're genuinely designed for sponsors running Phase I/II studies rather than retrofitted from big pharma requirements.

The most useful decision frame for growth-stage sponsors isn't "which platform has the most features" — it's "which platform matches our organizational profile at our current stage." US sponsors typically prioritize time-to-FPI, study build autonomy, and cost predictability; EMEA and APAC sponsors typically weight compliance credentials, vendor stability, and multi-language site support. Your QA team's validation bandwidth, your data management team's in-house configuration capability, and the phase trajectory of your pipeline are the three variables that determine which platform type will genuinely serve you.

Platform selection is one of the few infrastructure decisions in clinical operations where the switching cost is genuinely high. Re-validation, data migration, and retraining represent a substantial organizational burden — which means the right time to get this decision right is before your first study, not after your third.

Why Viedoc is the best EDC choice for growth-stage biotech

Growth-stage biotech sponsors need an EDC platform that keeps pace with their study build cycle, not one that creates a six-month procurement and deployment exercise before FPI. Viedoc's EDC software delivers study builds typically completed in 2--4 weeks, with a no-code Designer that allows your certified data managers to configure and amend studies in-house — no vendor-side programmer required, and no amendment queue to join every time your protocol evolves.

The pricing model is designed for sponsors who need budget predictability. Unlimited user seats, transparent study-based licensing, and no per-programmer fees for self-build clients give your clinical operations and finance teams a clear total cost of ownership from the outset. As your portfolio grows, Viedoc's modular eClinical suite — covering EDC, ePRO, eTMF, RTSM, Televisit, eSignature, and medical coding — expands with you on a single validated platform, without the re-validation overhead of adding new vendors to your stack.

Viedoc is ISO 27001 and SOC 2 Type II certified, compliant with 21 CFR Part 11, GDPR, EU Annex 11, and HIPAA, and backed by 24/7 customer support across global offices. The VIRP is included at every release, reducing your QA team's CSV workload with pre-built validation documentation. Founded in 2003 and now supporting 7,000+ studies across 75+ countries, Viedoc brings the track record your procurement team needs alongside the deployment speed your clinical operations team demands.

Book a demo or request a proposal and our team will walk you through study build speed, compliance credentials, and module depth in the context of your own trial portfolio.